Skip to main content
SpringerLink
Log in

Circulating galectin-3 on admission and prognosis in acute heart failure patients: a meta-analysis

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

Changes of serum galectin-3 have been associated with the pathogenesis of many cardiovascular diseases. The aim of the study was to evaluate the prognostic role of serum galectin-3 in patients with acute heart failure (AHF) in a meta-analysis. Follow-up studies evaluating the association between serum galectin-3 on admission and clinical outcomes in AHF patients were identified via search of PubMed and Embase databases. A random effects or a fixed effects model was applied to pool the results depending on the heterogeneity. Subgroup analysis was used to evaluate the influences of study characteristics on the outcomes. Overall, 7057 AHF patients from eighteen follow-up studies were included. Higher serum galectin-3 was associated with higher risks of all-cause mortality (adjusted risk ratio [RR], 1.58; p < 0.001), mortality/HF rehospitalization (RR, 1.68; p < 0.001), and cardiovascular mortality (RR, 1.29; p = 0.04), but not HF rehospitalization (RR, 1.24; p = 0.25) in AHF patients. Subgroup analyses showed that study characteristics including study design, sample size, age, gender, left ventricular ejection fraction, galectin-3 variable type, follow-up duration, and adjustment of type B natriuretic peptide did not significantly impact the results. Significant heterogeneities were detected for the outcomes of all-cause mortality and mortality/HF rehospitalization. However, trim-and-fill analyses by including the imputed studies to generate symmetrical funnel plots showed similar significant meta-analysis results. These results suggested that higher serum galectin-3 may be associated with poor prognosis in AHF patients. Further studies are needed to determine the mechanisms underlying the potential prognostic role of galectin-3 in AHF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Jordan LC, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, O’Flaherty M, Pandey A, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Spartano NL, Stokes A, Tirschwell DL, Tsao CW, Turakhia MP, VanWagner LB, Wilkins JT, Wong SS, Virani SS (2019) Heart Disease and Stroke Statistics-2019 update: a report from the American Heart Association. Circulation 139(10):e56–e528. https://doi.org/10.1161/CIR.0000000000000659

    Article  PubMed  Google Scholar 

  2. Sinnenberg L, Givertz MM (2019) Acute heart failure. Trends Cardiovasc Med. https://doi.org/10.1016/j.tcm.2019.03.007

    Article  PubMed  Google Scholar 

  3. van der Meer P, Gaggin HK, Dec GW (2019) ACC/AHA versus ESC guidelines on heart failure: JACC Guideline Comparison. J Am Coll Cardiol 73(21):2756–2768. https://doi.org/10.1016/j.jacc.2019.03.478

    Article  PubMed  Google Scholar 

  4. Michaud AM, Parker SIA, Ganshorn H, Ezekowitz JA, McRae AD (2018) Prediction of early adverse events in emergency department patients with acute heart failure: a systematic review. Can J Cardiol 34(2):168–179. https://doi.org/10.1016/j.cjca.2017.09.004

    Article  PubMed  Google Scholar 

  5. Tanaka TD, Sawano M, Ramani R, Friedman M, Kohsaka S (2018) Acute heart failure management in the USA and Japan: overview of practice patterns and review of evidence. ESC Heart Fail 5(5):931–947. https://doi.org/10.1002/ehf2.12305

    Article  PubMed  PubMed Central  Google Scholar 

  6. Rigopoulos AG, Bakogiannis C, de Vecchis R, Sakellaropoulos S, Ali M, Teren M, Matiakis M, Tschoepe C, Noutsias M (2019) Acute heart failure : an unmet medical need. Herz 44(1):53–55. https://doi.org/10.1007/s00059-017-4626-6

    Article  CAS  PubMed  Google Scholar 

  7. Gehlken C, Suthahar N, Meijers WC, de Boer RA (2018) Galectin-3 in heart failure: an update of the last 3 years. Heart Fail Clin 14(1):75–92. https://doi.org/10.1016/j.hfc.2017.08.009

    Article  PubMed  Google Scholar 

  8. Zhong X, Qian X, Chen G, Song X (2019) The role of galectin-3 in heart failure and cardiovascular disease. Clin Exp Pharmacol Physiol 46(3):197–203. https://doi.org/10.1111/1440-1681.13048

    Article  CAS  PubMed  Google Scholar 

  9. Chen A, Hou W, Zhang Y, Chen Y, He B (2015) Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis. Int J Cardiol 182:168–170. https://doi.org/10.1016/j.ijcard.2014.12.137

    Article  PubMed  Google Scholar 

  10. Imran TF, Shin HJ, Mathenge N, Wang F, Kim B, Joseph J, Gaziano JM, Djousse L (2017) Meta-analysis of the usefulness of plasma galectin-3 to predict the risk of mortality in patients with heart failure and in the general population. Am J Cardiol 119(1):57–64. https://doi.org/10.1016/j.amjcard.2016.09.019

    Article  CAS  PubMed  Google Scholar 

  11. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, Pinto YM (2006) Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 48(6):1217–1224. https://doi.org/10.1016/j.jacc.2006.03.061

    Article  CAS  PubMed  Google Scholar 

  12. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, van Veldhuisen DJ (2011) Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 43(1):60–68. https://doi.org/10.3109/07853890.2010.538080

    Article  CAS  PubMed  Google Scholar 

  13. Carrasco-Sanchez FJ, Aramburu-Bodas O, Salamanca-Bautista P, Morales-Rull JL, Galisteo-Almeda L, Paez-Rubio MI, Arias-Jimenez JL, Aguayo-Canela M, Perez-Calvo JI (2013) Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction. Int J Cardiol 169(3):177–182. https://doi.org/10.1016/j.ijcard.2013.08.081

    Article  PubMed  Google Scholar 

  14. van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, Muntendam P, van Veldhuisen DJ, de Boer RA (2013) Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail 6(2):219–226. https://doi.org/10.1161/CIRCHEARTFAILURE.112.000129

    Article  CAS  PubMed  Google Scholar 

  15. Meijers WC, de Boer RA, van Veldhuisen DJ, Jaarsma T, Hillege HL, Maisel AS, Di Somma S, Voors AA, Peacock WF (2015) Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH. Eur J Heart Fail 17(12):1271–1282. https://doi.org/10.1002/ejhf.407

    Article  CAS  PubMed  Google Scholar 

  16. Nunez J, Rabinovich GA, Sandino J, Mainar L, Palau P, Santas E, Villanueva MP, Nunez E, Bodi V, Chorro FJ, Minana G, Sanchis J (2015) Prognostic value of the interaction between galectin-3 and antigen carbohydrate 125 in acute heart failure. PLoS One 10(4):e0122360. https://doi.org/10.1371/journal.pone.0122360

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Behnes M, Bertsch T, Weiss C, Ahmad-Nejad P, Akin I, Fastner C, El-Battrawy I, Lang S, Neumaier M, Borggrefe M, Hoffmann U (2016) Triple head-to-head comparison of fibrotic biomarkers galectin-3, osteopontin and gremlin-1 for long-term prognosis in suspected and proven acute heart failure patients. Int J Cardiol 203:398–406. https://doi.org/10.1016/j.ijcard.2015.10.127

    Article  PubMed  Google Scholar 

  18. Beltrami M, Ruocco G, Dastidar AG, Franci B, Lucani B, Aloia E, Nuti R, Palazzuoli A (2016) Additional value of galectin-3 to BNP in acute heart failure patients with preserved ejection fraction. Clin Chim Acta 457:99–105. https://doi.org/10.1016/j.cca.2016.04.007

    Article  CAS  PubMed  Google Scholar 

  19. Demissei BG, Valente MA, Cleland JG, O’Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison B, Givertz MM, Bloomfield DM, Dittrich H, van der Meer P, van Veldhuisen DJ, Hillege HL, Voors AA (2016) Optimizing clinical use of biomarkers in high-risk acute heart failure patients. Eur J Heart Fail 18(3):269–280. https://doi.org/10.1002/ejhf.443

    Article  CAS  PubMed  Google Scholar 

  20. Feola M, Testa M, Leto L, Cardone M, Sola M, Rosso GL (2016) Role of galectin-3 and plasma B type-natriuretic peptide in predicting prognosis in discharged chronic heart failure patients. Medicine (Baltimore) 95(26):e4014. https://doi.org/10.1097/MD.0000000000004014

    Article  CAS  Google Scholar 

  21. Jackson CE, Haig C, Welsh P, Dalzell JR, Tsorlalis IK, McConnachie A, Preiss D, Anker SD, Sattar N, Petrie MC, Gardner RS, McMurray JJ (2016) The incremental prognostic and clinical value of multiple novel biomarkers in heart failure. Eur J Heart Fail 18(12):1491–1498. https://doi.org/10.1002/ejhf.543

    Article  CAS  PubMed  Google Scholar 

  22. Lala RI, Darabantiu D, Pilat L, Puschita M (2016) Galectin-3: a link between myocardial and arterial stiffening in patients with acute decompensated heart failure? Arq Bras Cardiol 106(2):121–129. https://doi.org/10.5935/abc.20150149

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Mueller T, Gegenhuber A, Leitner I, Poelz W, Haltmayer M, Dieplinger B (2016) Diagnostic and prognostic accuracy of galectin-3 and soluble ST2 for acute heart failure. Clin Chim Acta 463:158–164. https://doi.org/10.1016/j.cca.2016.10.034

    Article  CAS  PubMed  Google Scholar 

  24. Miro O, Gonzalez de la Presa B, Herrero-Puente P, Fernandez Bonifacio R, Mockel M, Mueller C, Casals G, Sandalinas S, Llorens P, Martin-Sanchez FJ, Jacob J, Bedini JL, Gil V (2017) The GALA study: relationship between galectin-3 serum levels and short- and long-term outcomes of patients with acute heart failure. Biomarkers 22(8):731–739. https://doi.org/10.1080/1354750X.2017.1319421

    Article  CAS  PubMed  Google Scholar 

  25. van Vark LC, Lesman-Leegte I, Baart SJ, Postmus D, Pinto YM, de Boer RA, Asselbergs FW, Wajon E, Orsel JG, Boersma E, Hillege HL, Akkerhuis KM (2017) Prognostic value of serial galectin-3 measurements in patients with acute heart failure. J Am Heart Assoc 6(12). https://doi.org/10.1161/JAHA.116.003700

  26. Lala RI, Lungeanu D, Darabantiu D, Pilat L, Puschita M (2018) Galectin-3 as a marker for clinical prognosis and cardiac remodeling in acute heart failure. Herz 43(2):146–155. https://doi.org/10.1007/s00059-017-4538-5

    Article  CAS  PubMed  Google Scholar 

  27. Testa M, Rosso GL, Ferreri C, Feola M (2018) The predictive value of plasma brain natriuretic peptide and galectin-3 in elderly patients admitted for heart failure. Diseases 6(4). https://doi.org/10.3390/diseases6040088

    Article  CAS  PubMed Central  Google Scholar 

  28. Zhang M, Meng Q, Qi X, Han Q, Wang F, Du B (2018) Comparison of multiple biomarkers for mortality prediction in patients with acute heart failure of ischemic and nonischemic etiology. Biomark Med 12(11):1207–1217. https://doi.org/10.2217/bmm-2018-0123

    Article  CAS  PubMed  Google Scholar 

  29. Chen YS, Gi WT, Liao TY, Lee MT, Lee SH, Hsu WT, Chang SS, Lee CC (2016) Using the galectin-3 test to predict mortality in heart failure patients: a systematic review and meta-analysis. Biomark Med 10(3):329–342. https://doi.org/10.2217/bmm.15.121

    Article  CAS  PubMed  Google Scholar 

  30. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15):2008–2012

    Article  CAS  PubMed  Google Scholar 

  31. Higgins J, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration http://www.cochranehandbook.org. Accessed 20 Jun 2019

  32. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P (2010) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 20 June 2019

  33. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558. https://doi.org/10.1002/sim.1186

    Article  PubMed  Google Scholar 

  34. Patsopoulos NA, Evangelou E, Ioannidis JP (2008) Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol 37(5):1148–1157. https://doi.org/10.1093/ije/dyn065

    Article  PubMed  PubMed Central  Google Scholar 

  35. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Santaguida PL, Don-Wauchope AC, Oremus M, McKelvie R, Ali U, Hill SA, Balion C, Booth RA, Brown JA, Bustamam A, Sohel N, Raina P (2014) BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review. Heart Fail Rev 19(4):453–470. https://doi.org/10.1007/s10741-014-9442-y

    Article  CAS  PubMed  Google Scholar 

  37. de Boer RA, van der Velde AR, Mueller C, van Veldhuisen DJ, Anker SD, Peacock WF, Adams KF, Maisel A (2014) Galectin-3: a modifiable risk factor in heart failure. Cardiovasc Drugs Ther 28(3):237–246. https://doi.org/10.1007/s10557-014-6520-2

    Article  CAS  PubMed  Google Scholar 

  38. Ibarrola J, Arrieta V, Sadaba R, Martinez-Martinez E, Garcia-Pena A, Alvarez V, Fernandez-Celis A, Gainza A, Santamaria E, Fernandez-Irigoyen J, Cachofeiro V, Zalba G, Fay R, Rossignol P, Lopez-Andres N (2018) Galectin-3 down-regulates antioxidant peroxiredoxin-4 in human cardiac fibroblasts: a new pathway to induce cardiac damage. Clin Sci (Lond) 132(13):1471–1485. https://doi.org/10.1042/CS20171389

    Article  CAS  Google Scholar 

  39. Souza BSF, Silva DN, Carvalho RH, Sampaio GLA, Paredes BD, Aragao Franca L, Azevedo CM, Vasconcelos JF, Meira CS, Neto PC, Macambira SG, da Silva KN, Allahdadi KJ, Tavora F, de Souza Neto JD, Dos Santos RR, Soares MBP (2017) Association of cardiac galectin-3 expression, myocarditis, and fibrosis in chronic chagas disease cardiomyopathy. Am J Pathol 187(5):1134–1146. https://doi.org/10.1016/j.ajpath.2017.01.016

    Article  CAS  PubMed  Google Scholar 

  40. Gonzalez GE, Rhaleb NE, D’Ambrosio MA, Nakagawa P, Liao TD, Peterson EL, Leung P, Dai X, Janic B, Liu YH, Yang XP, Carretero OA (2016) Cardiac-deleterious role of galectin-3 in chronic angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol 311(5):H1287–H1296. https://doi.org/10.1152/ajpheart.00096.2016

    Article  PubMed  PubMed Central  Google Scholar 

  41. Li X, Tang X, Lu J, Yuan S (2018) Therapeutic inhibition of galectin3 improves cardiomyocyte apoptosis and survival during heart failure. Mol Med Rep 17(3):4106–4112. https://doi.org/10.3892/mmr.2017.8323

    Article  CAS  PubMed  Google Scholar 

  42. Suthahar N, Meijers WC, Sillje HHW, Ho JE, Liu FT, de Boer RA (2018) Galectin-3 activation and inhibition in heart failure and cardiovascular disease: an update. Theranostics 8(3):593–609. https://doi.org/10.7150/thno.22196

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Intensive Care Unit, The First People’s Hospital of Xiangshan, No. 291 Donggu Road, Xiangshan County, Ningbo, 315700, China

    Hongsen Chen, Chensong Chen, Junjie Fang, Ren Wang & Wanshui Nie

Authors
  1. Hongsen Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chensong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Junjie Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ren Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wanshui Nie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hongsen Chen.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Hongsen Chen, Chensong Chen, Junjie Fang, Ren Wang, Wanshui Nie. These authors contributed equally to the work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, H., Chen, C., Fang, J. et al. Circulating galectin-3 on admission and prognosis in acute heart failure patients: a meta-analysis. Heart Fail Rev 25, 331–341 (2020). https://doi.org/10.1007/s10741-019-09858-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10741-019-09858-2

Keywords

Search

Navigation